Analysis of the Reasons for Hainan Haiyao's Popularity and Its Investment Value

Hainan Haiyao (000566.SZ) made it to the hot list on November 15, 2025, with a significant increase in market attention. There are multiple driving factors behind this phenomenon [0].

The Hainan Free Trade Port policy is one of the core factors driving Hainan Haiyao’s stock price up. As the Hainan Free Trade Port is about to be closed off, policy dividends such as ‘zero tariffs’ and ‘simplified tax system’ have brought substantial benefits to local pharmaceutical enterprises in Hainan [0]. These policies directly reduce the import cost of raw materials, increase the profit margin of enterprises, and make Hainan Free Trade Zone concept stocks the focus of market attention [0].

On November 14, 2025, the wholly-owned subsidiary of Hainan Haiyao obtained the approval for the consistency evaluation of the quality and efficacy of the generic drug meropenem for injection. This news became an important catalyst for the stock price to hit the daily limit [0]. Meropenem for injection is an important antibiotic product, and passing the consistency evaluation means that the product quality meets international standards, laying the foundation for subsequent market expansion.

The pharmaceutical sector saw obvious rotation in November 2025, with Hainan Free Trade Zone concept, pharmaceutical commerce, and flu concept leading the market gains [0]. As a local comprehensive pharmaceutical enterprise in Hainan, Hainan Haiyao benefited from both the overall strength of the pharmaceutical sector and the regional concept, becoming the focus of capital attention.

On November 14, 2025, Hainan Haiyao’s stock price closed at 6.77 yuan, with a daily increase of 10.08% and a daily limit trend. The turnover reached 651 million yuan, a significant increase compared to the previous period [0]. A MACD golden cross signal appeared on the technical side, indicating that it may enter a rising phase [0]. This trend of rising volume and price indicates that market funds have extremely high attention to this stock.

Despite the strong stock price performance, the company’s fundamentals still face challenges. In the first three quarters of 2025, it achieved a revenue of 1.9 billion yuan, and the net profit attributable to shareholders of listed companies was -84 million yuan. Although it narrowed year-on-year, it is still in a loss-making state [0]. Investors need to remain rational about this divergence between performance and stock price.

As a comprehensive pharmaceutical enterprise, Hainan Haiyao’s main business covers the R&D, production, and sales of pharmaceutical products such as chemical drugs and biological drugs [0]. The company has certain regional advantages in Hainan, but its competitiveness in the national pharmaceutical industry is relatively limited.

1. Performance Loss Risk
   : The company is still in a loss-making state, with insufficient fundamental support
2. Valuation Risk
   : The short-term increase is large, and there is a risk of valuation bubble
3. Policy Dependency Risk
   : Over-reliance on the policy dividends of the Hainan Free Trade Port; policy changes may affect the company’s performance

1. Sustained Policy Dividends
   : The construction of the Hainan Free Trade Port continues to advance, and policy dividends are expected to continue
2. Product Approval Effect
   : The approval of meropenem for injection is expected to bring new revenue growth points
3. Sector Rotation Opportunity
   : The rotation of the pharmaceutical sector may continue to drive the stock price up

Hainan Haiyao became a hot stock mainly due to the superposition of three positive factors: policy, product, and market [0]. The Hainan Free Trade Port policy provides macro-environment support, the approval of meropenem for injection provides micro-performance expectations, and the rotation of the pharmaceutical sector provides market sentiment support. However, investors need to pay attention to the fact that the company is still in a loss-making state and the correction risk brought by the excessive short-term increase.

From the time dimension, the Hainan Free Trade Port is about to be closed off, and related concept stocks may continue to receive market attention in the short term [0]. However, the long-term investment value still needs to focus on the improvement of the company’s fundamentals, especially the reversal of the loss situation and the progress of new product commercialization.